EYEG实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	10 000.00
平均成交量	469.00
市值	64.23M
EPS	$-0.420 ( 2021-11-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-02	From Stephen	Sell	250	Common Stock
2021-11-02	Mann Brenda	Sell	62	Common Stock
2021-10-04	Mann Brenda	Sell	62	Common Stock
2021-10-04	From Stephen	Sell	249	Common Stock
2021-09-02	From Stephen	Sell	253	Common Stock

INSIDER POWER
0.00
Last 98 transactions
Buy: 1 959 813 \| Sell: 207 057

EyeGate Pharmaceuticals 相关性

10 最正相关
BMTC	0.948
XPDI	0.926
FATE	0.912
TCDA	0.908
GRAY	0.905
ENPH	0.896
BCAB	0.895
ODT	0.887
HECCU	0.884
LHDX	0.879

10 最负相关
TIG	-0.936
CCRC	-0.928
FRGI	-0.917
ARNA	-0.903
DSPG	-0.899
ACIW	-0.899
NTES	-0.896
EXAS	-0.896
APEN	-0.896
GGAL	-0.895

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

EyeGate Pharmaceuticals 财务报表

Annual	2020
营收:	$12 059.00
毛利润:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2020
营收:	$12 059.00
毛利润:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2019
营收:	$2.69M
毛利润:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2018
营收:	$1.65M
毛利润:	$0.00 (0.00 %)
EPS:	$-4.50

Financial Reports:

No articles found.

EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.